Recursion Pharmaceuticals Inc (RXRX)
8.11
+0.27
(+3.44%)
USD |
NASDAQ |
Apr 26, 16:00
8.11
0.00 (0.00%)
After-Hours: 17:20
Recursion Pharmaceuticals Cash from Operations (TTM): -287.78M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -287.78M |
September 30, 2023 | -258.45M |
June 30, 2023 | -240.07M |
March 31, 2023 | -234.23M |
December 31, 2022 | -83.52M |
September 30, 2022 | -99.93M |
June 30, 2022 | -78.44M |
Date | Value |
---|---|
March 31, 2022 | -50.47M |
December 31, 2021 | -158.61M |
September 30, 2021 | -88.88M |
June 30, 2021 | -75.29M |
March 31, 2021 | -58.34M |
December 31, 2020 | -45.40M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-287.78M
Minimum
Dec 2023
-45.40M
Maximum
Dec 2020
-135.34M
Average
-88.88M
Median
Sep 2021
Cash from Operations (TTM) Benchmarks
Eli Lilly and Co | 4.240B |
Palatin Technologies Inc | -26.54M |
Oragenics Inc | -7.291M |
Editas Medicine Inc | -132.18M |
BioXcel Therapeutics Inc | -155.01M |